Researchers link organ-transplant drug to increased cancer risk

06/28/2010 | HealthDay News

A Dutch study showed that organ-rejection drug cyclosporine significantly increased the risk of cancer in patients younger than 50 who had a liver transplant between 1986 and 2007, particularly those who more recently underwent the procedure. Researchers also found that cyclosporine treatment was more likely than standard therapy tacrolimus to result in a more aggressive type of cancer.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI